Pharmacopeial Standards
United States Pharmacopeia (USP) standards are referenced throughout FDA regulations and are legally enforceable for pharmaceutical manufacturers. Affinity QMS provides the documentation, validation, and supplier management infrastructure to demonstrate USP compliance across USP <797>, USP <800>, and applicable general chapters.
Overview
The United States Pharmacopeia (USP) is an independent, nonprofit scientific organization that establishes public standards for medicines, food ingredients, and dietary supplements. USP standards are published in the United States Pharmacopeia–National Formulary (USP–NF), which is officially recognized as the compendium of drug quality standards under the Federal Food, Drug, and Cosmetic Act (FD&C Act). When a drug product claims to meet a USP monograph or general chapter standard — or when an FDA regulation specifically references USP — compliance with that standard becomes legally enforceable by FDA.
USP publishes two types of standards relevant to pharmaceutical and supplement manufacturers. USP monographs define standards for specific drug substances and products — identity, strength, quality, and purity specifications, reference standards, and test methods for a particular ingredient or finished product. USP general chapters are numbered standards (e.g., USP <797>, USP <1> through <999>) that apply to testing methods, equipment calibration, sterile preparations, analytical procedures, and other general quality practices. General chapters numbered below <1000> are mandatory if cited in a monograph or regulation; chapters <1000> and above are informational guidelines.
For 503B outsourcing facilities and compounding pharmacies preparing sterile preparations, USP <797> (pharmaceutical compounding of sterile preparations) and USP <800> (hazardous drugs — handling in healthcare settings) represent the most operationally significant USP chapters. For OTC drug manufacturers, the relevant general chapters include USP <2> (injections), USP <71> (sterility tests), USP <85> (bacterial endotoxins), USP <151> (pyrogen test), USP <661> (containers), and many others depending on dosage form. For dietary supplement manufacturers, USP <2750> and USP <2040> provide guidance on supplement testing and disintegration.
Key USP Chapters
USP <797>
The foundational standard for sterile compounding, applicable to 503A pharmacies, 503B outsourcing facilities, and hospital pharmacies. Covers beyond-use dating (BUD), ISO cleanroom classification, personnel training and competency, environmental monitoring, sterility testing, and quality control requirements for compounded sterile preparations (CSPs). The 2023 revised USP <797> significantly expanded contamination risk level categories and personnel competency requirements.
USP <800>
Establishes standards for safe handling of hazardous drugs (HDs) in healthcare settings including 503B facilities that compound HD preparations. Covers facility design (negative pressure rooms, C-PECs), personal protective equipment, decontamination and cleaning procedures, spill management, and training requirements. USP <800> applies to any facility that receives, stores, compounds, dispenses, or administers hazardous drug products as defined by NIOSH.
USP <1>–<999>
General chapters below <1000> are mandatory when referenced by a USP monograph. Key chapters for pharmaceutical manufacturers include <1> (injections), <71> (sterility tests), <85> (bacterial endotoxins), <621> (chromatography), <661> (containers — glass), <671> (containers — plastic), and <1225> (validation of compendial procedures). Each requires documented procedures, calibrated equipment, and validated methods that Affinity QMS tracks within Document Control and the Validation Engine.
USP <1>000+
USP chapters numbered <1000> and above are informational and not mandatory unless specifically referenced in regulations or monographs. Key informational chapters include <1058> (analytical instrument qualification), <1225> (validation of compendial procedures), and <2750> (nutritional supplement compounding). These serve as authoritative guidance for quality practices even when not directly enforceable, and FDA inspectors often reference them as industry baseline expectations.
Platform Mapping
| USP Requirement | Chapter / Reference | Affinity QMS Module | What It Does |
|---|---|---|---|
| Compounding procedures and SOPs | USP <797> §6 | Document Control | Controlled master formula records, compounding procedures, BUD documentation, cleanroom SOPs with version history and pharmacist approval workflows |
| Method Validation | USP <1225> | Validation Engine | Structured validation protocols for analytical procedures per USP <1225> requirements — accuracy, precision, specificity, linearity, range — with IQ/OQ/PQ protocol generation and electronic approval signatures |
| Non-conformance and CAPA | USP <797> §11 | CAPA Management | Out-of-specification (OOS) investigation workflows, environmental monitoring excursion CAPA, batch failure root cause analysis with documented resolution and recurrence prevention |
| Personnel Training and Competency | USP <797> §5 | Training Management | Compounding personnel training records, aseptic technique competency assessments (media fill test documentation), annual competency requalification tracking per USP <797> personnel requirements |
| Supplier and Ingredient Qualification | USP <797> §10 | Supplier Management | API and excipient supplier qualification records, CoA review and acceptance criteria documentation, supplier audit records, and hazardous drug supplier controls per USP <800> |
Who This Is For
Director of Quality at a 503B Facility
503B outsourcing facilities operating under FDA oversight and USP <797>/<800> must maintain extensive documentation. Affinity QMS manages the compounding SOPs, environmental monitoring CAPA, personnel qualification records, and supplier controls that FDA inspectors evaluate during 503B facility inspections.
Regulatory Affairs Manager at an OTC Drug Manufacturer
OTC drug manufacturers operating under 21 CFR Part 211 and referencing USP monographs need validation documentation for compendial methods and quality records demonstrating conformance to applicable USP general chapters. The Validation Engine module generates compliant IQ/OQ/PQ protocols aligned to USP <1225> methodology.
QA Manager at a Dietary Supplement Contract Manufacturer
Supplement CMOs supplying products marketed with USP verification marks or to customers requiring USP chapter compliance need a QMS that manages the testing documentation, supplier qualification records, and specification adherence evidence that USP compliance requires on an ongoing basis.
Common Questions
What is the difference between a USP monograph and a USP general chapter?
A USP monograph is a specific standard for a particular drug substance or drug product — it defines identity tests, assay procedures, related substance limits, and other quality attributes for that specific ingredient or product. For example, the monograph for Aspirin Tablets specifies the identity tests, dissolution test, assay method, and acceptance criteria that any product labeled as Aspirin Tablets must meet. A USP general chapter (e.g., USP <71>, USP <797>) applies broadly across many products and defines testing methods, equipment requirements, or operational standards. General chapters numbered below <1000> are mandatory when cited in a drug product's applicable monograph; chapters <1000> and above are informational guidance. Supplement manufacturers are not directly subject to monograph requirements the same way drug manufacturers are, but USP general guidance chapters are often referenced in customer contracts and third-party certification requirements.
How does USP compliance relate to FDA enforcement?
The Federal Food, Drug, and Cosmetic Act establishes the USP–NF as the official compendium of drug quality standards. FDA drug approval processes reference USP standards directly, and FDA's cGMP regulations (21 CFR Part 211) require that finished drug products meet USP standards when USP monographs exist for those products. Practically, this means FDA inspectors will cite USP general chapter non-conformances as cGMP violations during pharmaceutical inspections. For 503B outsourcing facilities, FDA's inspection program specifically evaluates USP <797> and USP <800> compliance as a core inspection element. Dietary supplement manufacturers are regulated under 21 CFR Part 111, which does not directly require USP compliance, but failure to meet USP standards can support an FDA adulteration or misbranding finding if USP standards are cited in the product labeling.
What did the 2023 revised USP <797> change for 503B facilities?
The 2023 revision of USP <797> (effective November 2023) made several significant changes that increased compliance burden for 503B outsourcing facilities and compounding pharmacies. The contamination risk level categories changed from "immediate use," "low risk," "medium risk," and "high risk" to "Category 1" (no endotoxin or sterility testing) and "Category 2" (requires sterility testing and endotoxin testing) with specific beyond-use dating (BUD) limits for each. Personnel competency requirements became more specific, requiring documented initial competency assessments and periodic requalification for each compounding activity. Environmental monitoring program requirements were expanded with more explicit sampling frequency, alert and action levels, and corrective action triggers. Garbing and hand hygiene assessment frequency also increased. Affinity QMS manages all of these documentation streams with configured workflows specific to USP <797> compliance.
Is there a separate USP certification for manufacturers?
USP does not directly certify manufacturers the way FDA registers facilities or SQF/BRCGS certify food companies. However, USP offers the USP Verified Dietary Supplement Mark program — a voluntary third-party verification program where USP tests products and audits facilities to confirm compliance with applicable USP quality standards. Products earning the USP Verified mark have been tested for identity, purity, strength, and composition against USP standards. The USP Verified mark is recognized by retailers like Costco and Target as a supplement quality signal. USP also operates reference standard programs, reference material programs, and laboratory services that manufacturers use to calibrate their testing programs to USP-traceable standards.
How does Affinity QMS support USP method validation documentation?
USP <1225> (Validation of Compendial Procedures) defines the validation characteristics required for different types of analytical procedures — identification tests, quantitative tests, limit tests, and dissolution tests — including accuracy, precision, specificity, limit of detection, limit of quantitation, linearity, and range. Affinity QMS's Validation Engine module generates structured validation protocol templates pre-configured to the USP <1225> framework. Each protocol captures the validation objective, procedure reference, acceptance criteria, and results section for each required validation characteristic. Electronic approval signatures from the QA department and the responsible scientist, version control, and storage within Document Control ensure that method validation records are complete, retrievable, and protected from unauthorized alteration — exactly what FDA inspectors expect to find during a pharmaceutical facility inspection.
Which Affinity QMS modules are most critical for USP <797> compliance?
For 503B outsourcing facilities and compounding pharmacies focused on USP <797> compliance, the four most critical Affinity QMS modules are Document Control (master formula records, BUD SOPs, environmental monitoring SOPs), Training Management (personnel qualification, aseptic competency assessments, annual requalification), CAPA Management (environmental monitoring excursion investigations, out-of-specification batch investigations), and Supplier Management (API/excipient supplier qualification, CoA review processes, hazardous drug controls). The Validation Engine module adds value specifically for facilities performing sterility testing, endotoxin testing, or analytical method validation for compounded products. Starting with Document Control and Training — the two modules most intensely scrutinized in FDA inspections of 503B facilities — provides the highest return on compliance investment in the shortest time.
Related Resources
See how Affinity QMS manages USP <797> documentation, compendial method validation, personnel qualification records, and supplier controls — so your team is ready when FDA arrives for inspection.
Book a Demo